TY - JOUR
T1 - The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors
AU - Membreno, Fernando E.
AU - Lawitz, Eric J.
PY - 2011/8
Y1 - 2011/8
N2 - This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.
AB - This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.
KW - Hepatitis C virus
KW - NS5B nucleoside inhibitors
KW - Non-nucleoside inhibitors
KW - Polymerase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=80052070428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052070428&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2011.05.003
DO - 10.1016/j.cld.2011.05.003
M3 - Review article
C2 - 21867940
AN - SCOPUS:80052070428
VL - 15
SP - 611
EP - 626
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
SN - 1089-3261
IS - 3
ER -